Kamada, Chiesi Farmaceutici Terminate Inhaled Alpha-1 Antitrypsin Therapy Deal Post author:Sam Post published:November 19, 2017 Post category:BioPharma Kamada now maintains full, worldwide commercial rights to its inhaled AAT. Source: BioSpace You Might Also Like Novartis AG Lays Out R&D Game Plan at Meet and Greet With 30 Execs in Boston May 31, 2017 Mako Medical to Create 153 Jobs in North Carolina Expansion December 10, 2017 Court Rules in Favor Of On Majority Of Allegations In Proposed Class Action Lawsuit April 17, 2017
